^
Association details:
Biomarker:ZMYM2-FGFR1 fusion
Cancer:Leukemia
Drug:Pemazyre (pemigatinib) (FGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Ex Vivo Drug Sensitivity Evaluation of a ZMYM2::FGFR1 Fusion-Positive 8p11 Myeloproliferative Syndrome (EMS) Leukemia

Published date:
11/02/2023
Excerpt:
Ex vivo drug sensitivity assays demonstrated the highly selective efficacy of FGFR inhibitors in ZMYM2::FGFR1 fusion-positive leukemia cells and a fusion-expressing BaF3 cell line….Ex vivo drug assays performed on ZMYM2::FGFR1 transformed BaF3 cells confirmed the efficacy of Pemigatinib and Ponatinib....Despite extensive screening, no other single agents or drug combinations exhibited increased effectiveness in the ZMYM2::FGFR1 transformed BaF3 cells except for Trametinib, a MEK inhibitor, and the combination of Belvarafenib (RAF inhibitor) and Gilteritinib (FLT3 inhibitor).
DOI:
https://doi.org/10.1182/blood-2023-186750